MX2019011196A - Neurotoxinas botulinas para uso en terapia. - Google Patents

Neurotoxinas botulinas para uso en terapia.

Info

Publication number
MX2019011196A
MX2019011196A MX2019011196A MX2019011196A MX2019011196A MX 2019011196 A MX2019011196 A MX 2019011196A MX 2019011196 A MX2019011196 A MX 2019011196A MX 2019011196 A MX2019011196 A MX 2019011196A MX 2019011196 A MX2019011196 A MX 2019011196A
Authority
MX
Mexico
Prior art keywords
acting
fast
therapy
botulinum toxin
botulinum neurotoxins
Prior art date
Application number
MX2019011196A
Other languages
English (en)
Inventor
Abushakra Sawsan
Ahmad Wajdie
Hasan Fauad
Jarpe Michael
Original Assignee
Bonti Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonti Inc filed Critical Bonti Inc
Publication of MX2019011196A publication Critical patent/MX2019011196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

En la presente se describen composiciones y métodos para usarse en procedimientos terapéuticos .
MX2019011196A 2017-03-22 2018-03-22 Neurotoxinas botulinas para uso en terapia. MX2019011196A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762474744P 2017-03-22 2017-03-22
US201762474749P 2017-03-22 2017-03-22
US201762508215P 2017-05-18 2017-05-18
PCT/US2018/023709 WO2018175688A1 (en) 2017-03-22 2018-03-22 Botulinum neurotoxins for use in therapy

Publications (1)

Publication Number Publication Date
MX2019011196A true MX2019011196A (es) 2020-01-20

Family

ID=63584698

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019011196A MX2019011196A (es) 2017-03-22 2018-03-22 Neurotoxinas botulinas para uso en terapia.
MX2022010186A MX2022010186A (es) 2017-03-22 2019-09-20 Neurotoxinas botulinas para uso en terapia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010186A MX2022010186A (es) 2017-03-22 2019-09-20 Neurotoxinas botulinas para uso en terapia.

Country Status (11)

Country Link
US (2) US11260114B2 (es)
EP (1) EP3600221A4 (es)
JP (2) JP2020511548A (es)
KR (1) KR20190126894A (es)
CN (1) CN110691579A (es)
AU (2) AU2018237198B2 (es)
BR (1) BR112019019743B1 (es)
CA (1) CA3057302A1 (es)
MX (2) MX2019011196A (es)
RU (2) RU2766147C2 (es)
WO (1) WO2018175688A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2766147C2 (ru) * 2017-03-22 2022-02-08 Бонти, Инк. Применение ботулинических нейротоксинов в лечении
AU2018254588A1 (en) * 2017-04-21 2019-11-07 Bonti, Inc. Initiating neurotoxin treatments
US20190183987A1 (en) * 2017-12-18 2019-06-20 Bonti, Inc. Neurotoxins for use in minimizing scarring
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
US11957740B2 (en) 2021-03-13 2024-04-16 Prime Bio, Inc. Complex of botulinum neurotoxin E and its binding protein as a formulation with enhanced potency
GB202206362D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2123837C1 (ru) * 1998-05-27 1998-12-27 Бритун Юлия Анатольевна Способ устранения морщин
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US20060067950A1 (en) * 2004-09-27 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins for use in wound healing
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US20090324647A1 (en) 2005-10-11 2009-12-31 Borodic Gary E Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use
US8361055B2 (en) * 2008-11-25 2013-01-29 Tucker Peter L Syringe and method for reconstitution of dry-form drugs and medicines
KR102005930B1 (ko) * 2008-12-31 2019-07-31 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
WO2011022357A2 (en) * 2009-08-17 2011-02-24 East Carolina University Fast acting snare-cleaving enzymes
JP2011157331A (ja) * 2010-02-03 2011-08-18 Chemo-Sero-Therapeutic Research Inst 高用量投与が可能なボツリヌス毒素製剤
WO2012135304A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Vagal nerve-based disorders
US9050337B2 (en) * 2011-06-27 2015-06-09 Sang Duck Kim Method for treating atrophic skin scars using a mixture of botulinum toxin and air
SG11201402131TA (en) * 2011-11-09 2014-08-28 Merz Pharma Gmbh & Co Kgaa Neurotoxins exhibiting shortened biological activity
WO2015126527A1 (en) * 2014-02-18 2015-08-27 Kaufman-Janette Joely Botulinum neurotoxin for use in the prophylactic treatment of cutaneous wounds
US20150283045A1 (en) * 2014-04-03 2015-10-08 Gary D. Hack Methods and compositions for enhancing and extending the cosmetic effects of non-surgical dermal interventions
EP3822286A1 (en) * 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Cationic neurotoxins
JP6955491B2 (ja) * 2015-10-29 2021-10-27 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法
EA201892820A1 (ru) * 2016-06-10 2019-10-31 Способ стабилизации белков
WO2018106339A1 (en) * 2016-12-06 2018-06-14 Bonti, Inc. Botulinum neurotoxins for use in tendon repair surgery
US20200023044A1 (en) * 2017-03-22 2020-01-23 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
RU2766147C2 (ru) * 2017-03-22 2022-02-08 Бонти, Инк. Применение ботулинических нейротоксинов в лечении
AU2018254588A1 (en) * 2017-04-21 2019-11-07 Bonti, Inc. Initiating neurotoxin treatments
AU2018258591A1 (en) * 2017-04-28 2019-11-07 Bonti, Inc. Botulinum neurotoxins production methods
US11952601B2 (en) * 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
CA3068292A1 (en) * 2017-06-26 2019-01-03 Bonti, Inc. Clostridial neurotoxin formulations and use
US20190183987A1 (en) * 2017-12-18 2019-06-20 Bonti, Inc. Neurotoxins for use in minimizing scarring
RU2020132826A (ru) * 2018-04-03 2022-05-04 Бонти, Инк. Нейротоксины для применения в ингибировании CGRP
US10464178B1 (en) * 2018-10-11 2019-11-05 Samuel J. Steeb Method and assembly for docking and retrieving a filament holding device
JP2022546517A (ja) * 2019-08-30 2022-11-04 イーオン バイオファーマ インコーポレイテッド 頭痛の治療に使用するための神経毒素組成物

Also Published As

Publication number Publication date
AU2018237198B2 (en) 2022-09-01
RU2022102750A (ru) 2022-03-28
EP3600221A4 (en) 2021-01-13
EP3600221A1 (en) 2020-02-05
US20230027850A1 (en) 2023-01-26
BR112019019743A2 (pt) 2020-04-14
AU2018237198A1 (en) 2019-10-31
RU2019132648A (ru) 2021-04-22
US11260114B2 (en) 2022-03-01
CN110691579A (zh) 2020-01-14
WO2018175688A1 (en) 2018-09-27
AU2022215253A1 (en) 2022-09-01
JP2023076463A (ja) 2023-06-01
CA3057302A1 (en) 2018-09-27
KR20190126894A (ko) 2019-11-12
MX2022010186A (es) 2022-09-19
BR112019019743B1 (pt) 2022-12-13
JP2020511548A (ja) 2020-04-16
RU2766147C2 (ru) 2022-02-08
RU2019132648A3 (es) 2021-06-23
US20200046814A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
MX2022010186A (es) Neurotoxinas botulinas para uso en terapia.
MX2018005256A (es) Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion.
MX2018009824A (es) Composiciones para el cuidado personal.
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
PH12020550821A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
MX2020011817A (es) Metodos para tratar el linfoma.
PH12019502721A1 (en) Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MX2018013507A (es) Composiciones y metodos para el tratamiento de la inflamacion o infeccion del ojo.
GB2571668A (en) Stem cell conditioned media for clinical and cosmetic applications
MX2019003258A (es) Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana.
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
EP3632450A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A DISEASE CAUSING FOOT PAIN CONSISTING OF BOTULIC TOXIN AND HYALURONIC ACID AND METHOD OF TREATMENT OF FOOT PAIN USING THE SAME
MX2019000006A (es) Composiciones para el tratamiento de estrias y ulceras de origen isquemico.
WO2021011875A8 (en) Compositions and methods for treating skin conditions